171 related articles for article (PubMed ID: 34171438)
1. New concepts regarding finite oral antiviral therapy for HBeAg-negative chronic hepatitis B.
Papatheodoridi M; Papatheodoridis G
J Hepatol; 2021 Dec; 75(6):1495-1496. PubMed ID: 34171438
[No Abstract] [Full Text] [Related]
2. Additional Measures After Stopping Nucleoside Analogues in HbeAg-Negative Chronic Hepatitis B: Better But Not Enough.
Lim SG; Tan YC
Gastroenterology; 2024 Jan; 166(1):23-24. PubMed ID: 37832923
[No Abstract] [Full Text] [Related]
3. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.
Chen CH; Hung CH; Wang JH; Lu SN; Hu TH; Lee CM
Clin Microbiol Infect; 2018 Sep; 24(9):997-1003. PubMed ID: 29288020
[TBL] [Abstract][Full Text] [Related]
4. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
[TBL] [Abstract][Full Text] [Related]
5. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
6. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
[No Abstract] [Full Text] [Related]
7. Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials.
Bedre RH; Raj U; Misra SP; Varadwaj PK
Indian J Gastroenterol; 2016 Mar; 35(2):75-82. PubMed ID: 27083430
[TBL] [Abstract][Full Text] [Related]
8. The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients.
Peng CW; Jeng WJ
Hepatol Int; 2021 Apr; 15(2):527-528. PubMed ID: 33904110
[No Abstract] [Full Text] [Related]
9. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
11. Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy.
Hadziyannis SJ
J Hepatol; 2002 Feb; 36(2):280-2. PubMed ID: 11830342
[No Abstract] [Full Text] [Related]
12. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
13. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
14. Can we stop nucleoside analogues before HBsAg loss?
Papatheodoridi M; Papatheodoridis G
J Viral Hepat; 2019 Aug; 26(8):936-941. PubMed ID: 30803099
[TBL] [Abstract][Full Text] [Related]
15. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.
Hsu WF; Chen CF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH; Wang HW; Huang GT; Peng CY
Liver Int; 2018 Apr; 38(4):627-635. PubMed ID: 28857411
[TBL] [Abstract][Full Text] [Related]
16. When can we stop nucleoside analogues in patients with chronic hepatitis B?
Chong CH; Lim SG
Liver Int; 2017 Jan; 37 Suppl 1():52-58. PubMed ID: 28052620
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B.
Choi J
Gut Liver; 2023 Mar; 17(2):179-180. PubMed ID: 36918269
[No Abstract] [Full Text] [Related]
18. Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up.
Karakaya F; Özer S; Kalkan Ç; Tüzün EA; Çalışkan A; Keskin O; Kabaçam G; Karatayli S; Karatayli E; Bozdayi AM; Idilman R; Yurdaydin C
Antivir Ther; 2017; 22(7):559-570. PubMed ID: 28240596
[TBL] [Abstract][Full Text] [Related]
19. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
20. [HBeAg-negative chronic hepatitis].
Ibragimova MM; Krel' PE; Abdurakhmanov DT
Ter Arkh; 2004; 76(2):87-91. PubMed ID: 15106425
[No Abstract] [Full Text] [Related]
[Next] [New Search]
